BioMarin Pharmaceuticals
BMRN
560 hedge funds and large institutions have $16.3B invested in BioMarin Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 197 increasing their positions, 205 reducing their positions, and 51 closing their positions.
31% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 51
2% more funds holding
Funds holding: 547 → 560 (+13)
0.22% less ownership
Funds ownership: 99.24% → 99.02% (-0.22%)
4% less repeat investments, than reductions
Existing positions increased: 197 | Existing positions reduced: 205
9% less capital invested
Capital invested by funds: $18B → $16.3B (-$1.71B)
19% less call options, than puts
Call options by funds: $181M | Put options by funds: $222M
57% less funds holding in top 10
Funds holding in top 10: 14 → 6 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$444M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$145M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$137M |
| 4 |
Millennium Management
New York
|
+$99.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$79.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$381M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$187M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$95.2M |
| 4 |
Parnassus Investments
San Francisco,
California
|
-$87.4M |
| 5 |
Morgan Stanley
New York
|
-$77.9M |
BMRN Hedge Fund Activity: Q1 2024 in Review
560 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2024, worth a combined $16.3B — down 9.5% from $18B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new BMRN positions and 51 closed out — a net gain of 16 holders — while 197 added to existing stakes and 205 trimmed.
The largest buyer was UBS Group, adding an estimated $444M. The largest seller was Capital Research Global Investors, cutting an estimated $381M.
- 560 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2024, up from 547 in Q4 2023.
- Funds reported $16.3B of BioMarin Pharmaceuticals stock for Q1 2024, down 9.5% quarter-over-quarter.
- 67 funds opened new BioMarin Pharmaceuticals positions in Q1 2024 and 51 closed out, a net change of +16 holders.
- The largest BioMarin Pharmaceuticals buyer in Q1 2024 was UBS Group, an estimated $444M added.
- The largest BioMarin Pharmaceuticals seller in Q1 2024 was Capital Research Global Investors, an estimated $381M sold.
Based on aggregated 13F filings for Q1 2024.